Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tapinarof cream is a topical aryl hydrocarbon receptor-modulating agent under investigation for the treatment of psoriasis. Tapinarof modulates the expression of interleukin-17 and the skin-barrier proteins filaggrin and loricrin. METHODS: We conducted two identical phase 3 randomized trials of tapinarof in patients with mild-to-severe plaque psoriasis. Adults with a baseline Physician's Global Assessment (PGA) score of 2 (mild) to 4 (severe) (on a scale from 0 to 4, with higher scores indicating more severe psoriasis) and a percent of total body-surface area affected of 3 to 20% were randomly assigned in a 2:1 ratio to use tapinarof 1% cream or vehicle cream once daily for 12 weeks. The primary end point, PGA response, was a PGA score of 0 (clear) or 1 (almost clear) and a decrease from baseline of at least 2 points at week 12. Secondary efficacy end points at week 12 were a reduction of at least 75% in the Psoriasis Area and Severity Index (PASI) score, a PGA score of 0 or 1, the mean change from baseline in the percent of body-surface area affected, and a reduction of at least 90% in the PASI score. Patient-reported outcomes were the mean changes from baseline to week 12 in the proportion of patients who had a decrease of at least 4 points in the Peak Pruritus Numeric Rating Scale (PP-NRS) score (range, 0 [no itch] to 10 [worst imaginable itch]), the PP-NRS total score, the Dermatology Life Quality Index total score, and the Psoriasis Symptom Diary score. RESULTS: In trials 1 and 2, a total of 692 and 674 patients, respectively, were screened, with 510 and 515 patients being enrolled. A PGA response occurred in 35.4% of the patients in the tapinarof group and in 6.0% of those in the vehicle group in trial 1 and in 40.2% and 6.3%, respectively, in trial 2 (P<0.001 for both comparisons). Results for secondary end points and patient-reported outcomes were generally in the same direction as those for the primary end point. Adverse events with tapinarof cream included folliculitis, nasopharyngitis, contact dermatitis, headache, upper respiratory tract infection, and pruritus. CONCLUSIONS: Tapinarof 1% cream once daily was superior to vehicle control in reducing the severity of plaque psoriasis over a period of 12 weeks but was associated with local adverse events and headache. Larger and longer trials are needed to evaluate the efficacy and safety of tapinarof cream as compared with existing treatments for psoriasis. (Funded by Dermavant Sciences; PSOARING 1 and 2 ClinicalTrials.gov numbers, NCT03956355 and NCT03983980, respectively.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study
Parisi, R., Iskandar, I. Y. K., Kontopantelis, E., Augustin, M., Griffiths, C. E. M., & Ashcroft, D. M. (2020) · BMJ · doi:10.1136/bmj.m1590 · Cited by 1,187
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
Menter, A., Strober, B. E., Kaplan, D. H., Kivelevitch, D., Prater, E. F., Stoff, B., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.11.057 · Cited by 969
Self-citationTapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans.
Smith, S. H., Jayawickreme, C., Rickard, D. J., Nicodeme, E., Bui, T., Simmons, C., Coquery, C. M., Neil, J., Pryor, W. M., Mayhew, D., et al. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.05.004 · Cited by 387
Elmets, C. A., Korman, N. J., Prater, E. F., Wong, E. B., Rupani, R. N., Kivelevitch, D., Armstrong, A. W., Connor, C., Cordoro, K. M., Davis, D. M. R., et al. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.07.087 · Cited by 352
Self-citationAryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Furue, M., Hashimoto-Hachiya, A., & Tsuji, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215424 · Cited by 215
Bissonnette, R., Stein Gold, L., Rubenstein, D. S., Tallman, A. M., & Armstrong, A. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.10.085 · Cited by 181
Self-citationPeppers, J., Paller, A. S., Maeda-Chubachi, T., Wu, S., Robbins, K., Gallagher, K., & Kraus, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.06.047 · Cited by 165
Paller, A. S., Stein Gold, L., Soung, J., Tallman, A. M., Rubenstein, D. S., & Gooderham, M. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.05.135 · Cited by 138
Self-citationBelinchón, I., Rivera, R., Blanch, C., Comellas, M., & Lizán, L. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s117006 · Cited by 108
Robbins, K., Bissonnette, R., Maeda-Chubachi, T., Ye, L., Peppers, J., Gallagher, K., & Kraus, J. E. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.10.037 · Cited by 93
Self-citationControl of immune-mediated pathology via the aryl hydrocarbon receptor
Wheeler, M. A., Rothhammer, V., & Quintana, F. J. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.767723 · Cited by 92
Bissonnette, R., Bolduc, C., Maari, C., Nigen, S., Webster, J. M., Tang, L., & Lyle, M. (2012) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2011.04332.x · Cited by 69
Self-citationTopical Therapies for Psoriasis: Improving Management Strategies and Patient Adherence
(2016) · Seminars in Cutaneous Medicine and Surgery · doi:10.12788/j.sder.2016.006 · Cited by 59
Puig, L., Carrascosa, J. M., Belinchón, I., Fernández‐Redondo, V., Carretero, G., Ruiz‐Carrascosa, J. C., Careaga, J. M., de la Cueva, P., Gárate, M. T., & Ribera, M. (2013) · Actas Dermo-Sifiliográficas · doi:10.1016/j.ad.2012.12.005 · Cited by 56
Stein Gold, L., Bhatia, N., Tallman, A. M., & Rubenstein, D. S. (2021) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.04.181 · Cited by 48
Self-citationSmith, S. G., McHale, K., Creech, K. L., Rickard, D. J., Jayawickreme, C. K., Wu, D., Rastinejad, F., & Rubenstein, D. S. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.605 · Cited by 10
Self-citation
Cited by
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Tsuji, G., Yamamura, K., Kawamura, K., Kido-Nakahara, M., Ito, T., & Nakahara, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914633 · Cited by 21
“Tapinarof cream was approved for use in psoriasis by the Food and Drug Administration (FDA) in May 2022 after its efficacy was confirmed in a clinical trial [104].”
MethodGalactomyces Ferment Filtrate Potentiates an Anti-Inflammaging System in Keratinocytes
Yan, X., Tsuji, G., Hashimoto-Hachiya, A., & Furue, M. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216338 · Cited by 20
Xie, D., Wang, Y., Li, J., Yang, T., Zhang, Y., Zhang, W., Doherty, M., Zhu, Y., Yang, Z., Wang, Y., et al. (2025) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2025.07.004 · Cited by 8
Metadata
- Authors
- Lebwohl, M. G., Stein Gold, L., Strober, B., Papp, K. A., Armstrong, A. W., Bagel, J., Kircik, L., Ehst, B., Hong, H. C.-H., Soung, J., Fromowitz, J., Guenthner, S., Piscitelli, S. C., Rubenstein, D. S., Brown, P. M., Tallman, A. M., & Bissonnette, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2219-2229
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4200054824
- Cited by
- 197
- References
- 16
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.